摘要
目的:探讨氯沙坦对早期糖尿病肾病(DN)患者转化生长因子TGF-β1、结缔组织生长因子(CTGF)水平的影响。方法:70例早期DN患者随机分组,对照组(35例)采用糖尿病(DM)常规治疗,治疗组(35例)在常规治疗基础上加用氯沙坦,疗程2个月。采用酶联免疫吸附法(ELISA)测定两组患者治疗前后尿TGF-β1、CTGF水平,同时观察血压、胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、空腹血糖、及餐后2h血糖、BUN、血肌酐(Scr)、24h尿白蛋白(UALB)等指标的变化。结果:与治疗前比较,患者治疗后尿TGF-β1和CTGF水平下降(P<0.05),UALB降低,血压、空腹血糖、餐后2h血糖、Scr、BUN指标改善(P<0.05),对照组治疗后尿TGF-β1升高(P<0.05),CTGF变化不大;后上述指标改善不如观察组。结论:氯沙坦可通过降低DN患者TGF-β1、CTGF水平而延缓DN的发展。
Objective：To investigate the effect of Losartan on transforming growth factor β1（TGF-β1 ） and connective tissue growth factor（CTGF） in patients with early diabetic nephropathy（DN） . Methods：70 patients with DN were randomly divided into the control group（n = 35） and the treatment group（ n = 35） . The control group was applied DN regular treatment and the treatment group was added to Losartan on the basis of regular treatment. Both of them were treated for 2 months. Urinary TGF-β1 and CTGF were determined with ELISA in two groups both before and after treatment. Blood pressure,TC,TG,HDL,LDL,fasting serum glucose,BUN,SCr and ULAB were also examined. Results：The levels of Urinary TGF-β1 and CTGF in the treatment group were significantly lower than those of pretreatment（P0.05） ,favorable changes of levels of other parameters（Blood pressure,fasting serum glucose,Scr,BUN,ULAB） were also demonstrated（P 0.05） . However,The levels of Urinary TGF-β1 in control group were higher than those of pretreatment（P 0.05） . The levels of urine of CTGF didn＇t change. The improvement in the above mentioned indexes were lower than those of in the treatment group. Conclusions：Losartan could delay the development of early DN by decreasing the levels of TGF-β1 and CTGF.
出处
《现代生物医学进展》
CAS
2010年第2期295-297,262,共4页
Progress in Modern Biomedicine
